secwatch.observer — SEC 8-K summary
======================================

Issuer:     Morphic Holding, Inc. (—)
CIK:        0001679363
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001679363-23-000074
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Morphic Q3 net loss $36.2M; CEO on medical leave; positive MORF-057 Phase 2a data
--------------------------------------------------------------------------------

- Net loss of $36.2M ($0.73/share) vs net income $30.0M ($0.78/share) a year ago; revenue $0.
- President Bruce Rogers appointed interim principal executive officer as CEO Praveen Tipirneni remains on medical leave.
- Positive EMERALD-1 Phase 2a data: MORF-057 achieved primary endpoint (RHI reduction 6.4 points, p=0.0019); mMCS remission 25.7% at week 12.
- Cash, equivalents, and marketable securities $725.1M, providing runway into H2 2027.
- EMERALD-2 Phase 2b enrollment on track; Phase 2b for Crohn's disease expected to begin H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1679363/000167936323000074/0001679363-23-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1679363/000167936323000074/morf-20231101.htm
  HTML page:      https://secwatch.observer/filing/0001679363-23-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer